CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 187 enrolled
Drug / intervention
Clarithromycin +1 moredrug
Likely dose
Clarithromycin 250 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02182492
NCT02182492N/ACompleted

Comparison of Different Efficacy of Macrolide and Glucocorticoid in the Treatment of Chronic Rhinosinusitis Patients After Endoscopic Sinus Surgery

Zheng Liu·interventional·Posted Jul 8, 2014·Updated Sep 25, 2018

In Brief

A clinical study evaluating Clarithromycin and Glucocorticoid for Chronic Rhinosinusitis and Endoscopic Sinus Surgery. Completed, enrolled 187 participants across 1 site.

Detailed Summary

Endoscopic sinus surgery (ESS) is widely considered to be the gold standard in the surgical management of chronic rhinosinusitis (CRS) that has failed maximal medical therapy. Nevertheless, the postoperation medical therapy was considered as a crucial procedure for the success of ESS. Both glucocorticoids and macrolide antibiotics have been recommended for the treatment of CRS, but their effect as postoperation medical therapies of ESS need more clinical data to clarify. The purpose of this prospective, randomized,study is to determine the effect of glucocorticoids and macrolide antibiotics for the postoperation medical therapy of ESS in different subtypes of CRS.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJul 8, 2014
Enrollment StartJan 1, 2014
Primary CompletionDec 1, 2015
Study CompletionJun 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 12.0 years ago

Interventions

Clarithromycindrug

Clarithromycin 250 mg tablet once daily for 3 months

Glucocorticoiddrug

Fluticasone propionate nasal spray 200 μg/d for 3 months